<DOC>
	<DOCNO>NCT00368979</DOCNO>
	<brief_summary>This study ass efficacy safety GI198745 0.5mg give daily 52 week Benign Prostatic Hyperplasia ( BPH ) patient .</brief_summary>
	<brief_title>Dutasteride ( GI198745 ) In Benign Prostatic Hyperplasia Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Only subject meet follow criterion screen phase enrol study . 1 . Diagnosis : BPH 2 . Age : ≥50 year 3 . Gender : Male 4 . Estimated prostate volume ≥30cc ( TRUS ) 5 . IPSS Symptom Score ( total 7 item ) ≥8 point 6 . Maximum flow rate ( Qmax ) ≤15mL/sec ( voided volume measure simultaneously ≤150mL ) * [ 1 ] 7 . Patients meet either follow regard tamsulosin HCl use : Patients tamsulosin HCl use : Patients receive tamsulosin HCl continuously least 4 week likely continue take tamsulosin HCl without change dosage administration drug end study treatment . Patients without tamsulosin HCl use : Patients n't receive tamsulosin HCl past 4 week unlikely use tamsulosin HCl end study treatment . 8 . Outpatients 9 . Patients person give write consent Patients apply follow criterion screen phase enrol study . 1 . Post void residual volume &gt; 250mL ( suprapubic ultrasound ) . 2 . History AUR within previous 12 week . 3 . Evidence history prostate cancer . 4 . PSA &gt; 10ng/mL [ patient PSA &gt; 4ng/mL , presence prostate cancer rule investigator/subinvestigator . DRE free/total PSA ratio consider , prostate biopsy conduct necessary ] . 5 . Previous surgery ( include balloon dilatation , thermotherapy stent placement ) minimally invasive technique BPH . 6 . Any cause BPH , may judgment investigator/subinvestigator , affect evaluation symptom urine flow ( e.g. , neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy , acute/chronic prostatitis , acute/chronic urinary tract infection ) . 7 . History unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmias* [ 2 ] , congestive heart failure cerebrovascular accident within previous 6 month ; diabetes mellitus peptic ulcer uncontrollable medical treatment . 8 . Liver function test ( AST , ALT , ALP ) &gt; 2 time upper limit normal . 9 . Serum cleatinine &gt; 1.8mg/dL . 10 . Use antiandrogen ( e.g. , chlormadinone acetate , allylesterenol ) BPH within previous 12 month . 11 . Use a1adrenoceptor blocker exclude tamsulosin HCl ( e.g. , prazosin HCl , urapidil slowrelease capsule formulation , terazosin HCl , naftopidil ) , plant extract preparation treatment BPH ( e.g. , Eviprostat , cernitin pollen extract ) , herbal medicine ( e.g. , hachimijiogan , goshajinkigan ) , drug ( e.g. , Paraprost ) , dietary herbal supplement ( e.g. , saw palmetto ) relief BPH symptom within previous 4 week . Use aadrenoceptor agonist ( e.g. , pseudoephedrine , phenyle [ 1 ] Subjects void volume &lt; 150 mL Qmax measurement enrol study may undergo remeasurement Qmax visit Week 0 study entry . [ 2 ] Of `` Degree II '' accord `` Grading Side Effects ( PMSB Notification No . 80 date June 29 , 1992 ) equivalent ( Appendix 4 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Benign Prostatic Hyperplasia BPH dutasteride</keyword>
</DOC>